Related Experiment Video

Updated: Mar 23, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.1K

[Sunitinib inhibits the expressions of co-stimulatory molecule ligands on dendritic cells]

Chao Ding1, Haixing Mai2, Lijun Chen3

  • 1Department of Urology, Clinical College, No. 307 Hospital of PLA, Anhui Medical University, Beijing 100071, China.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|April 8, 2016
PubMed
Abstract

Insights

Sunitinib treatment reduces key immune checkpoint ligands, programmed death ligand 1 (PD-L1) and B7-H4, on dendritic cells (DCs) from renal cell carcinoma patients. This suggests sunitinib may modulate immune responses in RCC.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is a significant malignancy.
  • Dendritic cells (DCs) play a crucial role in immune regulation.
  • Immune checkpoint molecules, such as PD-L1, are implicated in cancer immune evasion.

Purpose of the Study:

  • To evaluate the impact of sunitinib on co-stimulatory molecule ligand expression.
  • To investigate sunitinib's effect on programmed death ligand 1 (PD-L1), PD-L2, CD80, CD86, B7-H4, and HVEM.
  • To assess these changes on monocyte-derived dendritic cells (DCs) from RCC patients.

Main Methods:

  • Monocyte-derived DCs from RCC patients were cultured in vitro.
  • Cells were treated with sunitinib plus lipopolysaccharide (LPS), LPS alone, or dimethyl sulfoxide (DMSO).
  • Flow cytometry was employed to quantify the expression of target molecules.

Main Results:

  • Sunitinib-LPS co-treatment and LPS-only treatment induced typical dendritic cell morphology.
  • Compared to LPS treatment alone, sunitinib significantly decreased CD80, PD-L1, and B7-H4 expression on DCs.
  • The DMSO-treated group showed lower expression of PD-L1, PD-L2, CD80, CD86, B7-H4, and HVEM.

Conclusions:

  • Sunitinib inhibits the LPS-induced expression of CD80, PD-L1, and B7-H4 on dendritic cells.
  • These findings suggest a potential mechanism by which sunitinib may modulate the tumor immune microenvironment in RCC.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K